

1 **Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the**
2 **pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an**
3 **experimental design reflective of a treatment use case.**

4 Lee Tatham^{1,2*}, Anja Kipar^{3,4*}, Joanne Sharp^{1,2}, Edyta Kijak^{1,2}, Joanne Herriott^{1,2}, Megan Neary^{1,2}, Helen
5 Box^{1,2}, Eduardo Gallardo Toledo^{1,2}, Anthony Valentijn^{1,2}, Helen Cox^{1,2}, Henry Pertinez^{1,2}, Paul Curley^{1,2},
6 Usman Arshad^{1,2}, Rajith KR Rajoli^{1,2}, Steve Rannard^{2,5}, James Stewart⁴, Andrew Owen^{1,2 Δ} .

7

8 ¹Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative
9 Biology, University of Liverpool, Liverpool, UK.

10 ²Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK.

11 ³Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty,
12 University of Zurich, Winterthurerstrasse 268, 8057 Zurich, Switzerland.

13 ⁴Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological
14 Sciences, University of Liverpool, Liverpool, UK.

15 ⁵Department of Chemistry, University of Liverpool, Liverpool, UK.

16

17 *Both authors contributed equally to the work

18

19 ^{Δ} Corresponding author. E-mail: aowen@liverpool.ac.uk

20

21 Running title: Ronapreve antiviral efficacy in Delta, but not Omicron, infected mice.

22

23 **Abstract**

24 **Background:** Ronapreve demonstrated clinical application in post-exposure prophylaxis,
25 mild/moderate disease and in the treatment of seronegative patients with severe COVID19 prior to
26 the emergence of the Omicron variant in late 2021. Numerous reports have described loss of *in vitro*
27 neutralisation activity of Ronapreve and other monoclonal antibodies for BA.1 Omicron and
28 subsequent sub-lineages of the Omicron variant. With some exceptions, global policy makers have
29 recommended against the use of existing monoclonal antibodies in COVID19. Gaps in knowledge
30 regarding the mechanism of action of monoclonal antibodies are noted, and further preclinical study
31 will help understand positioning of new monoclonal antibodies under development.

32 **Objectives:** The purpose of this study was to investigate the impact of Ronapreve on compartmental
33 viral replication as a paradigm for a monoclonal antibody combination. The study also sought to
34 confirm absence of *in vivo* activity against BA.1 Omicron (B.1.1.529) relative to the Delta (B.1.617.2)
35 variant.

36 **Methods:** Virological efficacy of Ronapreve was assessed in K18-hACE2 mice inoculated with either
37 the SARS-CoV-2 Delta or Omicron variants. Viral replication in tissues was quantified using qRT-PCR to
38 measure sub-genomic viral RNA to the E gene (sgE) as a proxy. A histological examination in
39 combination with staining for viral antigen served to determine viral spread and associated damage.

40 **Results:** Ronapreve reduced sub-genomic viral RNA levels in lung and nasal turbinate, 4 and 6 days
41 post infection, for the Delta variant but not the Omicron variant of SARS-CoV-2 at doses 2-fold higher
42 than those shown to be active against previous variants of the virus. It also appeared to block brain
43 infection which is seen with high frequency in K18-hACE2 mice after Delta variant infection. At day 6,
44 the inflammatory response to lung infection with the Delta variant was altered to a mild multifocal
45 granulomatous inflammation in which the virus appeared to be confined. A similar tendency was also
46 observed in Omicron infected, Ronapreve-treated animals.

47 **Conclusions:** The current study provides evidence of an altered tissue response to the SARS-CoV-2
48 after treatment with a monoclonal antibody combination that retains neutralization activity. These
49 data also demonstrate that experimental designs that reflect the treatment use case are achievable
50 in animal models for monoclonal antibodies deployed against susceptible variants. Extreme caution
51 should be taken when interpreting prophylactic experimental designs when assessing plausibility of
52 monoclonal antibodies for treatment use cases.

53

54

55 Introduction

56 A concerted global effort since the emergence of SARS-CoV-2 in late 2019 resulted in a toolbox of
57 putative interventions that were brought through development at unprecedented speed. The rapid
58 development and implementation of vaccination programmes has had a transformational impact on
59 control of the pandemic in some countries but ongoing efforts for vaccine equity continue to be
60 critical.¹ In addition, first generation antiviral drugs have emerged from repurposed small molecules
61 from other antiviral development programmes, such as drugs originally developed for ebola, influenza
62 or prior coronaviruses. More potent antivirals continue to emerge, but considerable research is still
63 required to optimise deployment of existing agents (including evaluation of regimens composed of
64 drug combinations).^{2, 3}

65 Neutralising monoclonal antibodies targeting the spike protein on the surface of SARS-CoV-2 were
66 also brought forward with commendable speed, but the urgency of the pandemic necessitated that
67 key knowledge was not collected during the accelerated development process. Ronapreve (REGN-
68 COV2) is composed of two such monoclonal antibodies (casirivumab and imdevimab), and
69 demonstrated clinical efficacy against pre-Omicron SARS-CoV-2 variants in post-exposure
70 prophylaxis,⁴ early treatment,⁵ and in the treatment of seronegative patients with severe COVID19.⁶
71 With successive emergence of Omicron sub-lineages, all approved monoclonal antibodies have lost
72 varying degrees of neutralisation capability such that continued efficacy in all use cases is no longer
73 plausible based upon the current understanding of the pharmacokinetic-pharmacodynamic
74 relationship.⁷⁻⁹ As a result, no monoclonal antibodies are currently recommended by the NIH or
75 WHO.¹⁰⁻¹² Each antibody in Ronapreve exhibits molar potency against previous SARS-CoV-2 variants
76 which are orders of magnitude higher than current repurposed small molecule drugs such as
77 molnupiravir and nirmatrelvir^{10, 13} but they were given in combination to reduce the risk of emergence
78 of resistance as has been widely documented for monoclonal antibodies used against susceptible
79 variants as monotherapy.¹⁴⁻²⁰

80 Several variants of concern (VOC) have emerged over the past 2 years to which at least one of the
81 antibodies in Ronapreve has retained activity *in vitro*.²¹ Moreover, studies in K18-hACE2 transgenic
82 mice clearly demonstrated virological efficacy of Ronapreve against previous variants (not including
83 Delta which was not studied).²² Several studies have also investigated the activity of casirivumab and
84 imdevimab (alone or in combination) against pseudovirus engineered to express the BA.1 Omicron
85 spike protein or authentic virus.²³⁻²⁵ All studies have demonstrated compromised activity of the
86 Ronapreve combination in these assays. However, other studies reported residual activity of the
87 individual antibodies when studied in isolation, albeit with substantially lower activity. Unlike other
88 monoclonal antibodies, extremely high doses of casirivumab and imdevimab (up to 8000 mg
89 intravenously) have been studied safely and pharmacokinetics at these doses far exceed stringent
90 target concentrations developed by the manufacturers for ancestral SARS-CoV-2.⁵

91 Recent studies provided evidence that intraperitoneal administration of neutralising human
92 antibodies protect K18-hACE2 mice from lung infection and clinical disease in both prophylactic (hours
93 to 3 days prior to intranasal infection, using an ancestral SARS-CoV-2 and the Delta variant) and
94 therapeutic settings (up to 4 days post intranasal infection).^{26, 27} A study using neutralising murine
95 monoclonal antibodies demonstrated significant reduction of viral titres in the lungs at 2 days post
96 infection (dpi) i.e. the peak of lung infection in untreated mice, when mice were treated with the
97 antibody at 6 hours post intranasal infection. Similarly, prophylactic treatment (day -1) prior to
98 infection with an original virus isolate significantly reduced weight loss and viral titres in nasal
99 turbinate, lungs and brain at 5 dpi; interestingly, treatment at 5.5 hours post infection had the same
100 effect on body weight and viral loads in all tested organs except the lungs.²⁸

101 The purpose of this study was to investigate the ability of monoclonal antibody combinations to
102 mitigate pulmonary and neurological manifestations of SARS-CoV-2 infection using Ronapreve and the
103 Delta variant as a paradigm for activity against a susceptible variant. *In vivo* validation of prior *in vitro*
104 assay readouts for neutralisation of BA.1 Omicron by Ronapreve is also presented.

105 **Methods**

106 **Materials**

107 Materials were purchased and used as received without further purification: chloroform, isopropanol,
108 ethanol, phosphate buffered saline (PBS) and nuclease-free water were purchased from Fisher
109 Scientific (UK). Male K18-hACE2 mice were purchased from Charles River (France). Ronapreve
110 (casirivimab and imdevimab) was kindly provided by Roche (Switzerland). TRIzol™, GlycoBlue™,
111 Phasemaker™ tubes and TURBO DNA-free™ kit were purchased from Fisher Scientific (UK). GoTaq®
112 Probe 1-Step RT-qPCR System was purchased from Promega (US). SARS-CoV-2 (2019nCoV) CDC qPCR
113 Probe Assay was purchased from IDT (US). Precellys CKmix lysing tubes were purchased from Bertin
114 Instruments (France). For immunohistology, a rabbit anti-SARS-CoV nucleoprotein antibody was
115 purchased from Rocklands, the peroxidase blocking buffer and the Envision+System HRP Rabbit and
116 the diaminobenzidine from Agilent/DAKO. All other chemicals and reagents were purchased from
117 Merck (UK) and used as received, unless stated otherwise.

118 **Virus isolates**

119 The Delta variant (B.1.617.2) hCoV-19/England/SHEF-10E8F3B/2021 (GISAID accession number
120 EPI_ISL_1731019), was kindly provided by Prof. Wendy Barclay, Imperial College London, London, UK
121 through the Genotype-to-Phenotype National Virology Consortium (G2P-UK). Sequencing confirmed
122 it contained the spike protein mutations T19R, K77R, G142D, Δ156-157/R158G, A222V, L452R, T478K,
123 D614G, P681R, D950N. The Omicron variant (B.1.1.529/BA.1) isolate M21021166 was originally
124 isolated by Prof. Gavin Screaton, University of Oxford²⁴, UK and then obtained from Prof. Wendy
125 Barclay, Imperial College London, London, UK through the Genotype-to-Phenotype National Virology
126 Consortium (G2P-UK). Sequencing confirmed it contained the spike protein mutations A67V, Δ69-70,
127 T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S,
128 S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H,

129 N764K, A701V, D796Y, N856K, Q954H, N969K, L981F. The titres of all isolates were confirmed on Vero
130 E6 cells and the sequences of all stocks confirmed.

131 **Animal studies**

132 All work involving SARS-CoV-2 was performed at containment level 3 by staff equipped with respirator
133 airstream units with filtered air supply. Prior to the start of the study, all risk assessments and standard
134 operating procedures were approved by the University of Liverpool Biohazards Sub-Committee and
135 the UK Health and Safety Executive.

136 All animal studies were conducted in accordance with UK Home Office Animals Scientific Procedures
137 Act (ASPA, 1986). Additionally, all studies were approved by the local University of Liverpool Animal
138 Welfare and Ethical Review Body and performed under UK Home Office Project License PP4715265.
139 Male mice (20-30 g) carrying the human ACE2 gene under the control of the keratin 18 promoter (K18-
140 hACE2; formally B6.Cg-Tg(K18-ACE2)2Prlmn/J) were housed in individually-ventilated cages with
141 environmental enrichment under SPF barrier conditions and a 12-hour light/dark cycle at 21 °C ± 2 °C.
142 Free access to food and water was provided at all times.

143 Mice were randomly assigned into groups and acclimatized for 7 days. Mice in each group were
144 anaesthetised under 3% isoflurane and inoculated intranasally with 100 µL of either 10³ PFU of SARS-
145 CoV-2 Delta variant (B.1.617.2) or Omicron variant (B.1.1.529) in phosphate buffered saline (PBS).
146 After 24 hours, mice from each group were treated with a single dose (100 µL) of either the saline
147 control or 400 µg Ronapreve, diluted in saline, via intraperitoneal (IP) injection. All animals were
148 weighed and monitored daily throughout the experiment. At 4 and 6 days following infection, groups
149 of mice were sacrificed via a lethal IP injection of pentobarbitone, followed by cardiac puncture and
150 immediate exsanguination from the heart. Animals were immediately dissected and the right lung as
151 well as fragments from the nasal turbinates collected and frozen at -80°C for RNA extraction. The left
152 lung lobe and the head were fixed in 10% buffered formalin for 48 hours and then stored in 70%
153 ethanol until processing for histological and immunohistological examination.

154 **Quantification of viral RNA**

155 RNA isolation from lung and nasal turbinate samples, RNA quantification, and DNase treatment has
156 been detailed previously.²⁵

157 The viral RNA derived from the lung and nasal turbinate samples was quantified using a protocol for
158 quantifying the SARS-CoV-2 sub-genomic E gene RNA (sgE)²⁹ using the GoTaq® Probe 1-Step RT-qPCR
159 System (Promega).

160 Quantification of SARS-CoV-2 E SgRNA was completed utilising primers and probes previously
161 described elsewhere²⁹ and were used at 400 nM and 200 nM, respectively (IDT), using the GoTaq®
162 Probe 1-Step RT-qPCR System (Promega). Quantification of 18S RNA utilised previously described
163 primers and probe sequences,³⁰ and were used at 300 nM and 200 nM, respectively (IDT), using the
164 GoTaq® Probe 1-Step RT-qPCR System (Promega). Methods for the generation of the 18S and sgE RNA
165 standards have been outlined previously.³¹ Both PCR products were serially diluted to produce
166 standard curves in the range of 5×10^8 - 5 copies/reaction via a 10-fold serial dilution. DNase treated
167 RNA at 20,000 ng/mL or dH₂O were added to appropriate wells producing final reaction volumes of
168 20 µL. The prepared plates were run using a qTOWER³ Real-Time PCR Detector (Analytik Jena).
169 Thermal cycling conditions have been detailed previously.²⁵ The sgE data were normalised to 18S data
170 for subsequent quantitation.

171 **Statistical analysis**

172 An unpaired, two-tailed, t-test was used to compare the differences in lung and nasal turbinate viral
173 RNA between the control (saline) and Ronapreve treatment groups at days 4 and 6. A P-value of ≤ 0.05
174 was considered statistically significant. All statistical analysis was completed using GraphPad Prism
175 version 7.

176 **Histological and immunohistological analyses**

177 The fixed left lung was routinely paraffin wax embedded. Heads were sawn longitudinally in the
178 midline using a diamond saw (Exakt 300; Exakt) and the brain left in the skull. Heads were gently

179 decalcified in RDF (Biosystems) for twice 5 days, at room temperature (RT) and on a shaker, then both
180 halves paraffin wax embedded. Consecutive sections (3-5 μm) were prepared and stained with
181 hematoxylin eosin (HE) for histological examination or subjected to immunohistological staining to
182 detect SARS-CoV-2 antigen (performed in an autostainer; Agilent), using the horseradish peroxidase
183 (HRP) method and rabbit anti-SARS-CoV nucleocapsid protein (Rockland) as previously described³².
184 Briefly, sections were deparaffinized and rehydrated through graded alcohol. Antigen retrieval was
185 achieved by 20 min incubation in citrate buffer (pH 6.0) at 98 °C in a pressure cooker. This was followed
186 by incubation with the primary antibody (diluted 1:3,000 in dilution buffer; Dako) overnight at 4 °C, a
187 10 min incubation at RT with peroxidase blocking buffer (Agilent) and a 30 min incubation at RT with
188 Envision+System HRP Rabbit (Agilent). The reaction was visualized with diaminobenzidin (DAB; Dako)
189 for 10 min at RT. After counterstaining with hematoxylin for 2 s, sections were dehydrated and glass
190 coverslipped. In selected animals (see Supplemental Table S1), lungs were also stained for CD3 (T cell
191 marker), CD45R/B220 (B cell marker) and Iba1 (macrophage marker), as previously described³².
192

193 **Results**

194 **Body weight**

195 Weight was monitored throughout the study as a marker for health. Figure 1 shows mouse weights
196 relative to baseline (day 0; prior to SARS-CoV-2 inoculation). All animals displayed weight loss at day
197 2 post infection (9.3-14.3% of body weight); this was less rapid in the Delta variant infected animals,
198 albeit without statistical significance. Most animals regained some weight (2.1-5.2%) by day 3 and
199 most reached pre-infection levels (around 95%) by day 6 with the exception of the control Delta
200 variant infected animals which showed progressive weight loss after day 4, partly reaching the clinical
201 endpoint (up to 20% weight loss) by day 6.

202

203 **Effect of Ronapreve on viral replication**

204 To determine the viral load in animals infected with each variant and subsequently dosed with either
205 saline (controls) or Ronapreve, total RNA was extracted from the lung and nasal turbinate samples of
206 animals culled on days 4 and 6 post infection. Viral replication was quantified using qRT-PCR to
207 measure sub-genomic viral RNA to the E gene (sgE) as a proxy. The results are illustrated in Figure 2.
208 In SARS-CoV-2 Delta variant infected animals, the amount of sgE RNA was generally reduced after
209 Ronapreve treatment compared to the saline treated mice. At 4 dpi the difference was significant in
210 the nasal turbinates (log₁₀ fold decrease: -0.556, P=0.037) but not in the lung (log₁₀ fold reduction: -
211 0.602, P=0.065), whereas at 6 dpi, the difference was not significant in the nasal turbinates (log₁₀ fold
212 decrease: -1.369, P=0.111) but significant in the lung (log₁₀ fold reduction: -1.667, P=0.033).

213 In contrast, in the Omicron infected mice the amount of sgE RNA detected in the nasal turbinates was
214 only marginally reduced at both 4 dpi (log₁₀ fold decrease: -0.243, P=0.267) and 6 dpi (log₁₀ fold
215 decrease: -0.065, P=0.973) in the Ronapreve treated mice compared to the saline controls. The same
216 effect was observed in the lung at 4 dpi (log₁₀ fold reduction: -0.312, P=0.149) whereas it was similar

217 at 6 dpi (log₁₀ fold increase: 0.130, P=0.390). The results highlight the diminished *in vivo* antiviral
218 potency of Ronapreve against the Omicron variant.

219

220 **Differences in viral replication between Delta and Omicron variants**

221 Mice were challenged with a comparable amount of virus (10³ PFU) of both SARS-CoV-2 variants.
222 However, comparison of the sgE RNA levels in the tissues, of the saline treated animals at both time
223 points, showed that infection with the Omicron variant generally yielded lower viral loads. In the nasal
224 turbinate samples, a log₁₀ fold lower viral RNA level of -0.243, P=0.267 (4 dpi) and -2.043, P=0.099 (6
225 dpi) was observed in the Omicron group. In the lung, a log₁₀ fold lower viral RNA level of -0.353,
226 P=0.137 (4 dpi) and -0.561, P=0.085 (6 dpi) was observed. Detailed information on viral loads in
227 individual animals is provided in Supplemental Table S1. Similar trends have been reported in Omicron
228 infected mice displaying a lower viral load in both upper and lower respiratory tracts.³³

229

230 **The effect of Ronapreve on pulmonary changes and viral spread to the brain after infection with the** 231 **Delta and Omicron variants**

232 At 4 dpi, productive virus infection was also confirmed by immunohistochemistry in all groups of
233 infected mice. In saline treated animals, virus antigen was detected in epithelial cells in the nasal
234 mucosa in all Delta infected mice, but not in Omicron infected mice. This trend was consistent with
235 nasal turbinate PCR data with lower sgE RNA levels in the saline treated Omicron infected mice
236 compared to the Delta infected mice. Viral antigen was detected in the lung of 5 of the 6 Delta infected
237 mice. Infection was generally widespread and represented by numerous large, partly coalescing
238 patches of alveoli with positive type I and type II pneumocytes (Supplementary Figure S1a).
239 Histologically, this was accompanied by the presence of activated type II pneumocytes, occasional
240 syncytial cells and degenerate alveolar epithelial cells as well as scattered desquamated cells within

241 alveolar lumina and increased interstitial cellularity; mild vasculitis was also seen. Also in the Omicron
242 infected mice, viral antigen was detected in the lung (7 of 8 animals). Expression was seen in
243 disseminated small patches of alveoli with positive pneumocytes (Supplementary Figure S1b) and was
244 overall less abundant than in the Delta infected mice, confirming the virological results. Infection
245 accompanied by focal areas with increased interstitial cellularity and desquamation of a few alveolar
246 cells, some infiltrating lymphocytes and macrophages as well as occasional mild vasculitis. The lung
247 PCR data revealed no significant difference between the saline treated Omicron infected mice and the
248 Delta infected mice ($P=0.137$). Interestingly, animal C2.5 (Table S1) was negative for both viral antigen
249 and sgE RNA, demonstrating consistency between the immunohistochemistry and PCR data.

250 After Ronapreve treatment, at 4 dpi, virus antigen was detected in epithelial cells in the nasal mucosa
251 in 4 of the 8 Delta infected mice, and in 1 of the 8 Omicron infected mice. Viral antigen was detected
252 in the lung of 7 of the 8 Delta infected mice. It was generally less extensively expressed than in the
253 saline treated group and seen in the pneumocytes of small disseminated patches of alveoli
254 (Supplementary Figure S1c). Infection was accompanied by similar histological changes as in the
255 untreated mice, but these were less extensive. In Omicron infected mice, viral antigen was detected
256 in 5 of the 8 animals, with a similar extent and distribution as the Delta infected mice and the
257 untreated Omicron infected group alveoli (Supplementary Figure S1d), and with histological changes
258 similar to those seen in the untreated Omicron infected mice in nature and extent.

259 At 6 dpi, productive virus infection was still observed in all groups of infected mice. In saline treated
260 animals, virus antigen was detected in epithelial cells in the nasal mucosa in all Delta infected mice
261 but in none of the Omicron infected mice. Lower sgE RNA levels in the saline treated Omicron infected
262 mice compared to the Delta infected mice was observed, albeit not statistically significant ($P=0.099$).
263 Examination of the lungs revealed viral antigen in the lungs of 4 of the 6 Delta infected animals, mainly
264 in numerous, often large disseminated patches of alveoli (Supplementary Figure S1e), and most
265 intense in association with large focal areas of increased interstitial cellularity that contained activated

266 type II pneumocytes, occasional syncytial cells and degenerate and/or desquamated alveolar epithelial
267 cells. In Omicron infected mice, viral antigen expression was detected in all 8 animals, generally in
268 numerous disseminated, mainly small patches of alveoli (Supplementary Figure S1f). It was overall less
269 extensive than in the Delta infected animals at this time point, further supporting the virology results,
270 with lower sgE RNA levels in the saline treated Omicron infected mice compared to the Delta infected
271 mice, albeit not statistically significant ($P=0.085$). Infection was accompanied by mild histological
272 changes, represented by small focal areas with desquamated alveolar epithelial cells and mild
273 mononuclear infiltration.

274 After Ronapreve treatment, at 6 dpi, a different histopathological picture was observed in the Delta
275 infected mice. When viral antigen was detected (7/8 mice), its expression was very limited
276 (Supplementary Figure S1g). Histologically, multifocal small, delineated, dense parenchymal
277 mononuclear infiltrates were found (Fig. 3). These were comprised of macrophages (Iba1+), with
278 lesser T cells (CD3+) and B cells (CD45R+) and also seen to involve vessels, where a patchy vasculitis,
279 with focal infiltration of the vascular wall, stretching into a focal perivascular infiltrate, was observed
280 (Fig. 3). These lesions often contained a few infected alveolar epithelial cells and some free viral
281 antigen, consistent with debris of infected cells (Fig. 3f). Otherwise, viral antigen expression was
282 limited to epithelial cells in a few small patches of alveoli (Supplementary Figure S1g). All 7 Omicron
283 infected animals were found to harbor viral antigen in the lung (Supplementary Figure S1h), the extent
284 and distribution of viral antigen was similar to that at 4 dpi, seen as disseminated small patches of
285 alveoli with positive pneumocytes. The accompanying histological changes were generally mild and as
286 described for the control mice, though focal infiltrates similar to those seen in the Delta infected
287 treated mice were also seen, albeit overall less pronounced and less delineated. Detailed information
288 on histological findings, viral antigen expression and viral loads in individual animals is provided in
289 Supplemental Table S1.

290 We and others have previously shown that wildtype and VOC SARS-CoV-2s readily spread to the brain
291 in K18-hACEs mice; Omicron variants appear not to have the same effect, remaining unaltered and
292 without viral antigen expression³². The current study confirmed these findings. Brain infection was a
293 rather consistent finding in the untreated Delta infected animals. At 4 dpi, viral antigen was detected
294 multifocally in neurons in the brain in 4 of the 6 mice (Supplementary Fig S2a), all exhibiting viral
295 antigen also in the nasal mucosa, and in particular in the olfactory epithelium. Viral antigen was also
296 detected in nerve fibres or a variable amount of neurons in the olfactory bulb, consistent with viral
297 spread from the nasal mucosa, via the olfactory plate.³⁴ There was no evidence of an inflammatory
298 response. In contrast, none of the Omicron infected animals were found to harbor viral antigen in the
299 nasal mucosa and the brain (Supplemental Fig 2b). At 6 dpi, brain infection was confirmed by
300 immunohistology in 5 of the 6 Delta infected mice; viral antigen expression was still restricted to
301 neurons but was generally very widespread (Supplementary Fig S2e); in two mice it was accompanied
302 by mild perivascular mononuclear infiltrates consistent with a non-suppurative encephalitis. The nasal
303 mucosa, and in particular the olfactory epithelium, often also underlying nerve fibres were found to
304 harbor viral antigen also at this stage. Again, the Omicron infected mice did not show any viral antigen
305 expression in nasal mucosa and brain (Supplementary Fig S2f).

306 After Ronapreve treatment, there was no evidence of viral antigen expression in the brain of any Delta
307 infected animal at 4 and 6 dpi (each n=8; Supplementary Fig 2c and g); however, the nasal mucosa
308 harbored infected epithelial cells at both time points, in 4 of the 8 animals at 4 dpi, and in 6 of the 8
309 animals at 6 dpi. Omicron infected, Ronapreve treated animals were equally negative for viral antigen
310 in the brain and the nasal mucosa at both time points, with the exception of one mouse at 4 dpi.
311 Detailed information on histological findings and viral antigen expression in the brains of individual
312 animals is provided in Supplemental Table S1.

313

314

315 **Figure legends**

316 **Figure 1.** Mouse weights separated by treatment group and infection status. Weights are the
317 percentage of the initial weight recorded at day 0 prior to infection. Standard deviations are indicated
318 by the dashed plots.

319

320 **Figure 2.** Viral quantification of SARS-CoV-2 sub-genomic RNA (sgE), relative to 18S, using qRT-PCR
321 from nasal turbinate (a) and lung (b) samples harvested from each group on days 4 and 6 post
322 infection. Mice infected with the Delta variant were administered with a single IP dose of either saline
323 (n=12) or Ronapreve, 400 µg/mouse, in saline (n=16). Equally, mice infected with the Omicron variant
324 were administered with a single IP dose of either saline (n=16) or Ronapreve, 400 µg/mouse, in saline
325 (n=16). Data for individual animals are shown with the mean value represented by a black line. NS,
326 not significant; *, $P \leq 0.05$ (unpaired, two-tailed t-test).

327

328 **Figure 3.** Lungs, K18-hACE2 mice at day 6 post infection with 10^3 PFU of SARS-CoV-2 Delta variant
329 (B.1.617.2), followed after 24 hours by an intraperitoneal injection of 100 µL saline control or 400 µg
330 Ronapreve, diluted in saline. **a, b**) Saline treated animal (C3.1). The parenchyma shows a focal
331 consolidated area (asterisk) and several areas with increased cellularity (arrow) in the parenchyma in
332 which macrophages (Iba1+) are the dominant inflammatory cells (a: HE stain; b: Iba1
333 immunohistology; bars = 500 µm). **c-f**) Ronapreve treated animal (R3.2). **c, d**) The parenchyma exhibits
334 several well delineated dense inflammatory infiltrates (arrows) that are dominated by macrophages
335 (Iba1+). Inset (d): Closer view of a focal inflammatory infiltrate. Macrophages are the dominant cells
336 and are also seen to emigrate from a vessel (V; arrow). (c: HE stain; d: Iba1 immunohistology; bars =
337 500 µm). **e, f**) Closer view of a focal inflammatory infiltrate. Viral antigen is found within a few
338 pneumocytes (arrows) and cell free or phagocytosed within macrophages (arrowheads). Bars = 25 µm.

339

340 **Figure 4.** Heads with olfactory epithelium (OE) and brain, K18-hACE2 mice. SARS-CoV-2 N expression
341 at day 4 (a-d) and day 6 (e-h) post infection with 10^3 PFU of SARS-CoV-2 Delta variant (B.1.617.2; a, c,
342 e, g) or Omicron variant (b, d, f, h), followed after 24 hours by an intraperitoneal injection of 100 µL

343 saline control (a, b, e, f) or 400 μ g Ronapreve (c, d, g, h), diluted in saline. **a)** Delta variant infected
344 mouse (C1.1) treated with saline control, 4 dpi. The virus is widespread in the OE (arrow and inset
345 showing a large patch of positive epithelial cells (arrow) and a few individual positive epithelial cells
346 (arrowhead)) and has spread to the brain; there are patches of neurons positive for viral antigen, in
347 frontal cortex, cerebral nuclei (caudoputamen), hypothalamus/thalamus, midbrain and pons. The
348 arrowhead depicts a large patch of positive neurons in the frontal cortex of which a closer view is
349 provided in the inset. **b)** Omicron variant infected mouse (C2.3) treated with saline control, 4 dpi.
350 There is no evidence of viral antigen expression in the OE and the brain. **c)** Delta variant infected
351 mouse (R1.1) treated with Ronapreve, 4 dpi. There is no evidence of viral antigen expression in the
352 brain. The OE exhibits a small patch with positive epithelial cells. Inset: OE with viral antigen expression
353 in intact individual olfactory epithelial cells (arrowheads) and in degenerate cells in the lumen of the
354 nasal cavity. **d)** Omicron variant infected mouse (R2.5) treated with Ronapreve, 4 dpi. There is no
355 evidence of viral antigen expression in the OE and the brain. **e)** Delta variant infected mouse (C3.3)
356 treated with saline control, 6 dpi. There is widespread viral antigen expression in abundant neurons
357 throughout the brain including the olfactory bulb (left, arrow), with the exception of the cerebellum.
358 **f)** Omicron variant infected mouse (C4.1) treated with saline control, 6 dpi. There is no evidence of
359 viral antigen expression in the OE and the brain. **g)** Delta variant infected mouse (R3.3) treated with
360 Ronapreve, 6 dpi. There is no evidence of viral antigen expression in the OE and the brain. **h)** Omicron
361 variant infected mouse (C4.7) treated with Ronapreve, 6 dpi. here is no evidence of viral antigen
362 expression in the OE and the brain. Immunohistology, hematoxylin counterstain, and HE stain (insets).
363 Bars = 1 mm.

364

365 **Supplemental Figure S1.** Left lung, longitudinal sections, K18-hACE2 mice. SARS-CoV-2 N expression
366 at day 4 (a-d) and day 6 (e-h) post infection with 10^3 PFU of SARS-CoV-2 Delta variant (B.1.617.2; a, c,
367 e, g) or Omicron variant (b, d, f, h), followed after 24 hours by an intraperitoneal injection of 100 μ L
368 saline control (a, b, e, f) or 400 μ g Ronapreve (c, d, g, h), diluted in saline. **a)** Delta variant infected
369 mouse (C1.2) treated with saline control, 4 dpi. Abundant large, partly coalescing patches of alveoli
370 with positive epithelial cells are found disseminated throughout the parenchyma. **b)** Omicron variant
371 infected mouse (C2.1) treated with saline control, 4 dpi. There are multiple disseminated small patches
372 of alveoli with positive epithelial cells. A large patch (arrow) of positive alveoli is seen in association
373 with focal desquamation of alveolar epithelial cells (inset: arrows) and the presence of activated and
374 syncytial type II pneumocytes (inset: arrowheads). **c)** Delta variant infected mouse (R1.5) treated with
375 Ronapreve, 4 dpi. There are numerous small disseminated patches of alveoli with positive epithelial
376 cells, and larger patches (arrow) in association with focal activation and syncytia formation in type II

377 pneumocytes, desquamation of alveolar epithelial cells, occasional degenerate cells and a few
378 infiltrating lymphocytes and neutrophils (inset). **d)** Omicron variant infected mouse (R2.6) treated with
379 Ronapreve, 4 dpi. Viral antigen expression is seen in epithelial cells of random small patches of alveoli.
380 **e)** Delta variant infected mouse (C3.5) treated with saline control, 6 dpi. Multifocal extensive, partly
381 coalescing large patches of alveoli with positive epithelial cells are found disseminated throughout the
382 parenchyma. **f)** Omicron variant infected mouse (C4.8) treated with saline control, 6 dpi. There are
383 multiple disseminated, mainly small patches of alveoli with pos epithelial cells. **g)** Delta variant
384 infected mouse (R3.4) treated with Ronapreve, 6 dpi. There are disseminated very small patches of
385 alveoli with positive epithelial cells (inset). Positive cells are also observed in focal infiltrates (arrow;
386 see Fig. 3). **h)** Omicron variant infected mouse (C4.8) treated with Ronapreve, 6 dpi. There are
387 numerous disseminated, mainly small patches of alveoli with pos epithelial cells. Immunohistology,
388 hematoxylin counterstain, and HE stain (insets). Bars = 1 mm.

389

390

391

392 **Figures**

393 **Figure 1.**

394

395

396

397

398

399


400

401

402

403

404 **Figure 2.**




● Saline control, Delta

■ Ronapreve, Delta


○ Saline control, Omicron

▲ Ronapreve, Omicron

(a)



(b)




405

406

407

408 **Figure 3.**




409

410

411

412 **Figure 4**




413

414

415

416 **Supplemental Figure S1**



417

418 Discussion

419 The current study made use of a reliable animal model of SARS-CoV-2 infection to confirm and
420 characterize the effect of Ronapreve on established infections with the Delta variant and confirm its
421 ineffectiveness for BA.1 Omicron infections. Indeed, it provides increased certainty in the absence of
422 effect for Ronapreve which complements *in vitro* neutralisation data for this variant.^{23, 35} However, it
423 confirms efficacy for the Delta variant and provides evidence that monoclonal antibodies might limit
424 the virus spread into the brain when deployed against susceptible variants. In addition, it reveals
425 pathological processes that can develop in the lungs when Ronapreve is applied after the Delta variant
426 has reached the lungs.

427 A very rapid comparable decline in body weight was observed in all groups of mice, at 2 dpi, different
428 from previous studies that showed consistent weight drop only at 3 dpi. This early drop is likely a
429 response to the invasiveness and additional handling associated with the intraperitoneal dosing. The
430 weight gain towards day 3 moved body weights to levels observed in a previous study in which K18-
431 hACE2 transgenic mice were infected with the same virus variants at the same dose, but were not
432 treated any further.³³ By the end of the study, all but the saline-control animals infected with the Delta
433 variant had regained more weight. This observation is in agreement with the authors' previous
434 evaluation of the pathogenicity of these variants in K18 hACE2 transgenic mice.³³ Mice infected with
435 the Omicron variant generally carried less sub-genomic viral RNA than Delta variant-infected mice in
436 both nasal turbinates and lungs at 4 and 6 dpi, which is consistent with previous reports and lower
437 viral replication of Omicron in the respiratory tract and lungs at these time points.³³ The histological
438 and immunohistological results support this finding. At both time points, viral antigen expression was
439 less widespread after Omicron infection, and the histological changes, representing focal areas of
440 alveolar damage with associated inflammatory response, were less severe.

441 Consistent with the clinical evidence through body weight measurements, levels of sub-genomic RNA
442 were reduced in both nasal turbinates and lung of mice infected with the Delta variant after Ronapreve

443 treatment compared to controls, at both time points. This finding was complemented by the results
444 of the histological and immunohistological examinations. While the control group at 4 dpi exhibited,
445 in the majority, multifocal areas with activation and syncytia formation of type II pneumocytes, some
446 desquamation of alveolar epithelial cells and occasional vasculitis, with extensive multifocal viral
447 antigen expression, the lungs of the Ronapreve treated mice were either found unaltered and free of
448 viral antigen, or exhibited a few small focal areas with alveolar damage and small patches of infected
449 alveoli, but no evidence of vasculitis. This suggests that post-exposure Ronapreve treatment reduces
450 pulmonary damage. Two days later, the difference between saline control and Ronapreve treated
451 mice was even greater. In the former, the lesions observed at 4 dpi were found to persist and the
452 accompanying inflammatory response had intensified, resulting in larger consolidated areas and
453 perivascular leukocyte infiltrates, with extensive multifocal viral antigen expression in large patches
454 of alveoli. After Ronapreve treatment, a different type and extent of inflammation and viral antigen
455 expression was observed. Viral antigen was only seen in a few very small patches of alveolar epithelial
456 cells and within small, delineated focal macrophage dominated, i.e. granulomatous parenchymal
457 infiltrates that also harbored viral antigen. Their proximity to and frequent continuity with identical
458 focal infiltrates of vascular walls and the presence of viral antigen not only within pneumocytes but
459 also within macrophages in these lesions indicate that they result from focal recruitment of
460 macrophages into the parenchyma in response to virus. Ronapreve represents human antibodies that
461 target the spike protein on the surface of SARS-CoV-2. After a single application, the antibodies will
462 not have induced an immune response in the mice, instead they will likely have bound to the Fc
463 receptors of the murine macrophages.³⁶ Considering that the granulomatous reaction was not
464 observed in the saline controls, it is likely that it represents the local response to antibody-opsonised
465 virus that is phagocytosed by macrophages. A previous study that histologically examined the lungs of
466 mice treated with a neutralizing antibody at 2 dpi as late as 21 days post infection found unaltered
467 lungs with only scarce lymphoid aggregates,²⁷ indicating that these local processes can dissolve with
468 time. Murine models are generally robust for identifying potential pathological effects of therapeutic

469 interventions. The implications of these findings to clinical deployment of monoclonal antibodies is
470 currently uncertain, but further robust assessment incorporating morphological measures in parallel
471 to virological measures is warranted.

472 The immunohistological examination also revealed a further positive effect of the Ronapreve
473 treatment. As expected, the Delta variant had already spread to the brain in some animals by day 4
474 and was found widespread in the brain at 6 dpi in mice that had received the saline control.³² At the
475 later time point it had induced a mild inflammatory response in some animals. After Ronapreve
476 treatment, there was no evidence of viral antigen expression in the brain, and no inflammatory
477 change. These findings suggest that Ronapreve treatment post exposure might inhibit viral spread into
478 the brain. Whether infection of the brain is completely blocked or only substantially reduced, requires
479 further investigations, particularly at the molecular level. In light of previous studies which showed
480 that, in K18-hACE2 mice, the virus reaches the brain predominantly via the olfactory route^{32, 34} and
481 considering Ronapreve treatment reduces viral loads in the nasal turbinates it is probable that
482 Ronapreve inhibits brain infection by reducing the risk of virus spread from the olfactory epithelium
483 to the underlying nerves, then the olfactory bulb and into the brain.

484 Conversely, no significant impact of Ronapreve on sub-genomic RNA over 6 days was observed in mice
485 infected with BA.1 Omicron, which is consistent with a loss of neutralisation of this variant. The doses
486 used in the current study were 2-fold higher than those for which virological efficacy was
487 demonstrated in K18-hACE2 transgenic mice previously for other variants²² which reinforces the
488 conclusion that activity against Omicron is ablated for Ronapreve. The immunohistological results
489 further support the virological findings, as they indicate no or only mild reduction of viral antigen
490 expression after Ronapreve treatment. At 6 dpi, a limited granulomatous response was observed in
491 some lungs, suggesting some virus opsonization, though only to a very low extent.

492 Curiously, the magnitude of the reduction in Delta sub-genomic RNA was lower in the present study
493 than that reported for total RNA in the previous study despite the higher dose.²² At the time of writing,

494 the authors are unaware of other studies that have investigated the efficacy of Ronapreve for Delta in
495 this model, but neutralisation of Delta was not meaningfully compromised *in vitro*.¹³ Differences in
496 the endpoint (sub-genomic versus total RNA measurements) make it difficult to draw firm conclusions
497 from these observations but underscore the importance of *in vivo* evaluation of the efficacy of
498 interventions against new and future variants.

499 The experimental design employed here reflects treatment whereby the intervention was applied
500 subsequent to the inoculation of the animals with virus. Several other studies that have sought to
501 assess continued efficacy of monoclonal antibodies against later Omicron sub-lineages have utilized
502 prophylactic designs where the antibody is administered prior to inoculation of the animals with virus
503 ³⁷⁻³⁹. Because of the differences in viral load when the intervention is introduced, it is well established
504 for antiviral interventions that the bar is much higher to achieve efficacy in treatment than it is for
505 prophylaxis. The data presented here clearly demonstrate that *in vivo* designs reflecting the intended
506 treatment use case are achievable and demonstrate efficacy for monoclonal antibodies against
507 susceptible variants. Extreme caution should be taken when interpreting *in vivo* data from
508 prophylactic designs when making an assessment of the likely continued efficacy in treatment, and
509 where animal data are used to support candidacy of interventions, *in vivo* studies should be designed
510 to be reflective of the intended use case in humans.

511 A limitation of the current study is that serum concentrations of the Ronapreve antibodies were not
512 measured in order to facilitate a comparison with exposures observed in humans. However, the lack
513 of virological efficacy for BA.1 Omicron despite a demonstrable impact upon Delta, coupled with the
514 higher doses used here compared with a previous study with earlier variants²² allows for confidence
515 in the outcome despite this deficit.

516

517

518 **Acknowledgements**

519 The authors are grateful to the technical staff at the Histology Laboratory, Institute of Veterinary
520 Pathology, Vetsuisse Faculty, University of Zurich, for excellent technical support.

521

522 **Funding**

523 This work was supported by Unitaid as a COVID-19 supplement to project LONGEVITY. AO
524 acknowledges funding by Wellcome Trust (222489/Z/21/Z); EPSRC (EP/R024804/1, EP/S012265/1);
525 and NIH (R01AI134091, R24AI118397). JPS acknowledges funding from MRC (MR/W005611/1,
526 MR/R010145/1); BBSRC (BB/R00904X/1, BB/R018863/1, BB/N022505/1); and Innovate UK
527 (TS/V012967/1). AK has received support from the Swiss National Science Foundation (SNSF; IZSEZO
528 213289) and from the European Union's Horizon Europe research and innovation programme under
529 grant agreement No 101057553 and the Swiss State Secretariat for Education, Research and
530 Innovation (SERI) under contract number 22.00094.

531

532 **Transparency declarations**

533 AO and SR are Directors of Tandem Nano Ltd and co-inventors of patents relating to drug delivery. AO
534 has been co-investigator on funding received by the University of Liverpool from ViiV Healthcare and
535 Gilead Sciences unrelated to COVID-19 in the past 3 years. AO has received personal fees from Gilead
536 and Assembly Biosciences in the past 3 years unrelated to COVID-19. AO was a member of the Trial
537 Management Group for the AGILE phase I/II platform trial until January 2023 and AGILE received
538 funding from Ridgeback and GSK in the past 3 years for which AO was not a co-investigator. SR has
539 received research funding from ViiV and AstraZeneca and consultancy from Gilead not related to the
540 current paper. No other conflicts are declared by the authors.

541

542 References

- 543 1. WHO. Vaccine Equity. <https://www.who.int/campaigns/vaccine-equity> 2022.
- 544 2. Peter Horby WB, Julian Hiscox, Meera Chand, Judith Breuer, Emma Sherwood, Andrew
545 Owen. Antiviral drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19.
546 *New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)* -
547 [https://www.gov.uk/government/publications/nervtag-antiviral-drug-resistance-and-the-use-of-](https://www.gov.uk/government/publications/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021)
548 [directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021/nervtag-antiviral-drug-](https://www.gov.uk/government/publications/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021)
549 [resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021](https://www.gov.uk/government/publications/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19-8-december-2021) 2021.
- 550 3. Hiscox JA, Khoo SH, Stewart JP et al. Shutting the gate before the horse has bolted: is it time
551 for a conversation about SARS-CoV-2 and antiviral drug resistance? *Journal of Antimicrobial*
552 *Chemotherapy* 2021; **76**: 2230-3.
- 553 4. O'Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV Antibody
554 Combination to Prevent Covid-19. *New England Journal of Medicine* 2021; **385**: 1184-95.
- 555 5. Weinreich DM, Sivapalasingam S, Norton T et al. REGEN-COV Antibody Combination and
556 Outcomes in Outpatients with Covid-19. *New England Journal of Medicine* 2021; **385**: e81.
- 557 6. Abani O, Abbas A, Abbas F et al. Casirivimab and imdevimab in patients admitted to hospital
558 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet* 2022;
559 **399**: 665-76.
- 560 7. Owen A, Diaz JV, Guyatt G et al. WHO Living Guidelines on antivirals for COVID-19 are
561 evidence-based. *The Lancet* 2022; **400**: 2196-8.
- 562 8. Emergency Use Authorization (EUA) for Sotrovimab Center of Drug Evaluation and Research
563 (CDER) Memorandum *The US Food and Drug Administration (FDA)*
564 <https://www.fda.gov/media/157556/download> 2022.
- 565 9. Guidance - Responding to emerging COVID-19 variants of concern. *UK Medicines &*
566 *Healthcare Products Regulatory Agency* - [https://www.gov.uk/government/publications/responding-](https://www.gov.uk/government/publications/responding-to-emerging-covid-19-variants-of-concern/responding-to-emerging-covid-19-variants-of-concern)
567 [to-emerging-covid-19-variants-of-concern/responding-to-emerging-covid-19-variants-of-concern](https://www.gov.uk/government/publications/responding-to-emerging-covid-19-variants-of-concern/responding-to-emerging-covid-19-variants-of-concern)
568 2023.
- 569 10. Lamontagne F, Agoritsas T, Siemieniuk R et al. A living WHO guideline on drugs to prevent
570 covid-19. *BMJ* 2021: n526.
- 571 11. National Institutes of Health. *Coronavirus Disease 2019 (COVID-19) Treatment Guidelines*
572 <https://www.covid19treatmentguidelines.nih.gov/> 2023.
- 573 12. Lamontagne F, Agarwal A, Rochweg B et al. A living WHO guideline on drugs for covid-19.
574 *BMJ* 2020: m3379.
- 575 13. Fact Sheet for Health Care Providers EUA of Casirivimab and imdevimab. *The US Food and*
576 *Drug Administration (FDA)* <https://www.fda.gov/media/145611/download> 2021.
- 577 14. Choudhary MC, Chew KW, Deo R et al. Emergence of SARS-CoV-2 Resistance with
578 Monoclonal Antibody Therapy. Cold Spring Harbor Laboratory, 2021.
- 579 15. Rockett R, Basile K, Maddocks S et al. Resistance Mutations in SARS-CoV-2 Delta Variant
580 after Sotrovimab Use. *New England Journal of Medicine* 2022; **386**: 1477-9.
- 581 16. Gliga S, Lübke N, Killer A et al. Rapid Selection of Sotrovimab Escape Variants in Severe Acute
582 Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients. *Clin Infect*
583 *Dis* 2023; **76**: 408-15.
- 584 17. Andrés C, González-Sánchez A, Jiménez M et al. Emergence of Delta and Omicron variants
585 carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab
586 treatment with long-term viral excretion. *Clinical Microbiology and Infection* 2023; **29**: 240-6.
- 587 18. Birnie E, Biemond JJ, Appelman B et al. Development of Resistance-Associated Mutations
588 After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron
589 Variant. *JAMA* 2022; **328**: 1104.

- 590 19. Huygens S, Oude Munnink B, Gharbharan A et al. Sotrovimab Resistance and Viral
591 Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute
592 Respiratory Syndrome Coronavirus 2 Omicron Variant. *Clin Infect Dis* 2023; **76**: e507-e9.
- 593 20. Vellas C, Trémeaux P, Del Bello A et al. Resistance mutations in SARS-CoV-2 omicron variant
594 in patients treated with sotrovimab. *Clin Microbiol Infect* 2022; **28**: 1297-9.
- 595 21. National Center for Advancing Translational Sciences (NCATS), OpenData Portal, SARS-CoV-2
596 Variants & Therapeutics. <https://opendatancats.nih.gov/variant/activity> 2022.
- 597 22. Chen RE, Winkler ES, Case JB et al. In vivo monoclonal antibody efficacy against SARS-CoV-2
598 variant strains. *Nature* 2021; **596**: 103-8.
- 599 23. Vanblargan LA, Errico JM, Halfmann PJ et al. An infectious SARS-CoV-2 B.1.1.529 Omicron
600 virus escapes neutralization by therapeutic monoclonal antibodies. *Nature Medicine* 2022; **28**: 490-5.
- 601 24. Dejnirattisai W, Shaw RH, Supasa P et al. Reduced neutralisation of SARS-CoV-2 omicron
602 B.1.1.529 variant by post-immunisation serum. *The Lancet* 2022; **399**: 234-6.
- 603 25. Neary M, Box H, Sharp J et al. Evaluation of intranasal nafamostat or camostat for SARS-CoV-
604 2 chemoprophylaxis in Syrian golden hamsters. Cold Spring Harbor Laboratory, 2021.
- 605 26. Rouet R, Henry JY, Johansen MD et al. Broadly neutralizing SARS-CoV-2 antibodies through
606 epitope-based selection from convalescent patients. *Nature communications* 2023; **14**.
- 607 27. Rosenfeld R, Noy-Porat T, Mechaly A et al. Post-exposure protection of SARS-CoV-2 lethal
608 infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. *Nature*
609 *communications* 2021; **12**.
- 610 28. Morgan MS, Yan K, Le TT et al. Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein
611 Suitable for Multiple Applications for Current Variants of Concern. *Viruses* 2022; **15**: 139.
- 612 29. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients
613 with COVID-2019. *Nature* 2020; **581**: 465-9.
- 614 30. Ashraf N, Zino S, Macintyre A et al. Altered sirtuin expression is associated with node-
615 positive breast cancer. *British Journal of Cancer* 2006; **95**: 1056-61.
- 616 31. Salzer R, Clark JJ, Vaysburd M et al. Single-dose immunisation with a multimerised SARS-
617 CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. *FEBS*
618 *Letters* 2021; **595**: 2323-40.
- 619 32. Seehusen F, Clark JJ, Sharma P et al. Neuroinvasion and Neurotropism by SARS-CoV-2
620 Variants in the K18-hACE2 Mouse. *Viruses* 2022; **14**.
- 621 33. Bentley EG, Kirby A, Sharma P et al. SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less
622 severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. Cold
623 Spring Harbor Laboratory, 2021.
- 624 34. Carossino M, Kenney D, O'Connell AK et al. Fatal Neurodissemination and SARS-CoV-2
625 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression. *Viruses* 2022; **14**: 535.
- 626 35. Ikemura N, Taminishi S, Inaba T et al. Engineered ACE2 counteracts vaccine-evading SARS-
627 CoV-2 Omicron variant. Cold Spring Harbor Laboratory, 2021.
- 628 36. Dekkers G, Bentlage AEH, Stegmann TC et al. Affinity of human IgG subclasses to mouse Fc
629 gamma receptors. *mAbs* 2017; **9**: 767-73.
- 630 37. Addetia A, Piccoli L, Case JB et al. Therapeutic and vaccine-induced cross-reactive antibodies
631 with effector function against emerging Omicron variants. Cold Spring Harbor Laboratory, 2023.
- 632 38. Driouich J-S, Bernardin O, Touret F et al. In vivo activity of Sotrovimab against BQ.1.1
633 Omicron sublineage. Cold Spring Harbor Laboratory, 2023.
- 634 39. Hérate C, Marlin R, Touret F et al. Sotrovimab retains activity against SARS-CoV-2 Omicron
635 variant BQ.1.1 in a non-human primate model. Cold Spring Harbor Laboratory, 2023.